9
total announcements
524400.BO · 15 min delayed
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has issued letters to shareholders who have not registered their email addresses, providing a weblink to access the Annual Report for Financial Year 2025-26.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has submitted its Annual Report for the Financial Year 2025-26, along with the Notice of 33rd Annual General Meeting to be held on 30th September 2026.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has announced the 33rd Annual General Meeting (AGM) to be held on September 30, 2026, with e-voting period from September 27 to 29, 2026. The meeting will consider re-appointment of auditors, related party transactions, and other business.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has announced the e-voting period for its 33rd AGM, scheduled to be held on 30.09.2026. The e-voting period will commence from 27.09.2026 and ends on 29.09.2026.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has announced the book closure for its 33rd Annual General Meeting (AGM) from September 24, 2026, to September 30, 2026, inclusive.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has announced the re-appointment of Mrs. Abha Agrawal as a Non-Executive Non-Independent Director of the Company post attaining the age of 75 years. The Board of Directors also approved the Unaudited Financial Results for the quarter ended 30th June, 2026, and accepted the revised remuneration proposal of Mr. Sumit Agrawal, Chief Financial Officer of the Company. The meeting also discussed the upgradation project of the manufacturing facility for compliance with Revised Schedule M.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd announced unaudited financial results for the quarter ended 30th June, 2026, along with a limited review report from the statutory auditor. The board approved the results, re-appointed a director, and discussed the upgradation project of the manufacturing facility.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd's board meeting outcome: approved unaudited financial results for Q1 2026, re-appointed Mrs. Abha Agrawal as non-executive non-independent director, approved revised remuneration for CFO, discussed upgradation project of manufacturing facility, and amended notice for 33rd AGM.
Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 to consider and approve the unaudited financial results for the quarter ended 30th June, 2026.